IP Library Granted Patent US 8,017,150
Granted Patent B2
US 8,017,150 · App. 12/107,389 · Granted Sep 13, 2011

Polyethylene oxide-based films and drug delivery systems made therefrom

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,017,150
App. No.
12/107,389
Granted
Sep 13, 2011
Kind
B2
Abstract

The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. The films contain a polymer component, which includes polyethylene oxide optionally blended with hydrophilic cellulosic polymers. Desirably, the films also contain a pharmaceutical and/or cosmetic active agent with no more than a 10% variance of the active agent pharmaceutical and/or cosmetic active agent per unit area of the film.

Claims (30)

1. A mucosally-adhesive water-soluble film product comprising:

an analgesic opiate pharmaceutical active; and

at least one water-soluble polymer component consisting of polyethylene oxide in combination with a hydrophilic cellulosic polymer;

wherein:

the water-soluble polymer component comprises greater than 75% polyethylene oxide and up to 25% hydrophilic cellulosic polymer;

the polyethylene oxide comprises one or more low molecular weight polyethylene oxides and one or more higher molecular weight polyethylene oxides, the molecular weight of the low molecular weight polyethylene oxide being in the range 100,000 to 300,000 and the molecular weight of the higher molecular weight polyethylene oxide being in the range 600,000 to 900,000; and

the polyethylene oxide of low molecular weight comprises about 60% or more in the polymer component.

2. The film product according to claim 1 , wherein said film product has a viscosity of about 1,000 cps to about 40,000 cps.

3. The film product according to claim 1 , wherein said film product has a thickness of about 3 mils to about 6 mils.

4. The film product according to claim 1 , further comprising an additional pharmaceutical active.

5. The film product according to claim 1 , further comprising one or more sweeteners.

6. The film product according to claim 5 , wherein said one or more sweeteners comprise a hydrogenated starch hydrolysate.

7. The film product according to claim 5 , wherein said one or more sweeteners comprise the potassium salt of 3,6-dihydro-6-methyl-1-1-1,2,3-oxathiazin-4-one-2,2-dioxide.

8. The film product according to claim 1 , further comprising one or more flavors.

9. The film product according to claim 1 , further comprising one or more buffers.

10. A mucosally-adhesive water-soluble film product comprising:

an analgesic opiate pharmaceutical active; and

at least one water-soluble polymer component consisting of polyethylene oxide in combination with a hydrophilic cellulosic polymer;

wherein:

the water-soluble polymer component comprises the hydrophilic cellulosic polymer in a ratio of up to about 4:1 with the polyethylene oxide;

the polyethylene oxide comprises one or more low molecular weight polyethylene oxides and one or more higher molecular weight polyethylene oxides, the molecular weight of the low molecular weight polyethylene oxide being in the range 100,000 to 300,000 and the molecular weight of the higher molecular weight polyethylene oxide being in the range 600,000 to 900,000; and

the polyethylene oxide of low molecular weight comprises about 60% or more in the polymer component.

11. The film product according to claim 10 , wherein said film product has a viscosity of about 1,000 cps to about 40,000 cps.

12. The film product according to claim 10 , wherein said film product has a thickness of about 3 mils to about 6 mils.

13. The film product according to claim 10 , further comprising an additional pharmaceutical active.

14. The film product according to claim 10 , further comprising one or more sweeteners.

15. The film product according to claim 14 , wherein said one or more sweeteners comprise a hydrogenated starch hydrolysate.

16. The film product according to claim 14 , wherein said one or more sweeteners comprise the potassium salt of 3,6-dihydro-6-methyl-1-1-1,2,3-oxathiazin-4-one-2,2-dioxide.

17. The film product according to claim 10 , further comprising one or more flavors.

18. The film product according to claim 10 , further comprising one or more buffers.

Assignments (11)
RELEASE OF SECURITY INTEREST Recorded May 13, 2026
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
To: AQUESTIVE THERAPEUTICS, INC.
Reel/Frame 075646/0258 →
SECURITY INTEREST Recorded Nov 2, 2023
From: AQUESTIVE THERAPEUTICS, INC.
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 065446/0494 →
RELEASE OF SECURITY INTEREST Recorded Nov 1, 2023
From: U.S. BANK TRUST COMPANY NATIONAL ASSOCIATION (AS SUCCESSOR IN INTEREST TO U.S BANK NATIONAL ASSOCIATION)
To: AQUESTIVE THERAPEUTICS, INC.
Reel/Frame 065426/0642 →
RELEASE OF SECURITY INTEREST Recorded Jul 15, 2019
From: PERCEPTIVE CREDIT HOLDINGS, LP
To: AQUESTIVE THERAPEUTICS, INC.; MONOSOL RX, INC.; MSRX US, LLC
Reel/Frame 049757/0733 →
SECURITY INTEREST Recorded Jul 15, 2019
From: AQUESTIVE THERAPEUTICS, INC.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 049758/0082 →
AMENDMENT TO PATENT SECURITY AGREEMENT RECORDED AT REEL/FRAME 039707/0194 Recorded Jan 30, 2018
From: AQUESTIVE THERAPEUTICS, INC.
To: PERCEPTIVE CREDIT HOLDINGS, LP
Reel/Frame 045279/0802 →
CHANGE OF NAME Recorded Jan 29, 2018
From: MONOSOL RX, LLC
To: AQUESTIVE THERAPEUTICS, INC.
Reel/Frame 045196/0389 →
RELEASE OF SECURITY INTEREST Recorded Aug 22, 2016
From: WHITE OAK GLOBAL ADVISORS, LLC
To: MONOSOL RX, LLC
Reel/Frame 039774/0782 →
SECURITY INTEREST Recorded Aug 16, 2016
From: MONOSOL RX, LLC; MONOSOL RX, INC.; MSRX US, LLC
To: PERCEPTIVE CREDIT HOLDINGS, LP
Reel/Frame 039707/0194 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2013
From: YANG, ROBERT K.; FUISZ, RICHARD C.; MYERS, GARRY L.; FUISZ, JOSEPH M.
To: MONOSOL RX, LLC
Reel/Frame 031040/0808 →
SECURITY AGREEMENT Recorded Dec 18, 2012
From: MONOSOL RX, LLC
To: WHITE OAK GLOBAL ADVISORS, LLC, AS AGENT
Reel/Frame 029490/0156 →